166 related articles for article (PubMed ID: 12504632)
1. Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers.
Wiener JR; Windham TC; Estrella VC; Parikh NU; Thall PF; Deavers MT; Bast RC; Mills GB; Gallick GE
Gynecol Oncol; 2003 Jan; 88(1):73-9. PubMed ID: 12504632
[TBL] [Abstract][Full Text] [Related]
2. Activation of Src family kinases in Neu-induced mammary tumors correlates with their association with distinct sets of tyrosine phosphorylated proteins in vivo.
Muthuswamy SK; Muller WJ
Oncogene; 1995 Nov; 11(9):1801-10. PubMed ID: 7478608
[TBL] [Abstract][Full Text] [Related]
3. Src tyrosine kinase promotes survival and resistance to chemotherapeutics in a mouse ovarian cancer cell line.
Pengetnze Y; Steed M; Roby KF; Terranova PF; Taylor CC
Biochem Biophys Res Commun; 2003 Sep; 309(2):377-83. PubMed ID: 12951060
[TBL] [Abstract][Full Text] [Related]
4. Decreased Src tyrosine kinase activity inhibits malignant human ovarian cancer tumor growth in a nude mouse model.
Wiener JR; Nakano K; Kruzelock RP; Bucana CD; Bast RC; Gallick GE
Clin Cancer Res; 1999 Aug; 5(8):2164-70. PubMed ID: 10473101
[TBL] [Abstract][Full Text] [Related]
5. Dasatinib + Gefitinib, a non platinum-based combination with enhanced growth inhibitory, anti-migratory and anti-invasive potency against human ovarian cancer cells.
Thibault B; Jean-Claude B
J Ovarian Res; 2017 Apr; 10(1):31. PubMed ID: 28446239
[TBL] [Abstract][Full Text] [Related]
6. Src inhibition enhances paclitaxel cytotoxicity in ovarian cancer cells by caspase-9-independent activation of caspase-3.
Chen T; Pengetnze Y; Taylor CC
Mol Cancer Ther; 2005 Feb; 4(2):217-24. PubMed ID: 15713893
[TBL] [Abstract][Full Text] [Related]
7. Overexpression and activation of the tyrosine kinase Src in human pancreatic carcinoma.
Lutz MP; Esser IB; Flossmann-Kast BB; Vogelmann R; Lührs H; Friess H; Büchler MW; Adler G
Biochem Biophys Res Commun; 1998 Feb; 243(2):503-8. PubMed ID: 9480838
[TBL] [Abstract][Full Text] [Related]
8. SRC tyrosine kinase and multidrug resistance protein-1 inhibitions act independently but cooperatively to restore paclitaxel sensitivity to paclitaxel-resistant ovarian cancer cells.
George JA; Chen T; Taylor CC
Cancer Res; 2005 Nov; 65(22):10381-8. PubMed ID: 16288028
[TBL] [Abstract][Full Text] [Related]
9. Her-2/neu expression and amplification in early stage ovarian surface epithelial neoplasms.
Wu Y; Soslow RA; Marshall DS; Leitao M; Chen B
Gynecol Oncol; 2004 Dec; 95(3):570-5. PubMed ID: 15581965
[TBL] [Abstract][Full Text] [Related]
10. Cyclooxygenase-2 (COX-2), epidermal growth factor receptor (EGFR), and Her-2/neu expression in ovarian cancer.
Ferrandina G; Ranelletti FO; Lauriola L; Fanfani F; Legge F; Mottolese M; Nicotra MR; Natali PG; Zakut VH; Scambia G
Gynecol Oncol; 2002 May; 85(2):305-10. PubMed ID: 11972392
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of Her-2/NEU in epithelial ovarian carcinoma induces vascular endothelial growth factor C by activating NF-kappa B: implications for malignant ascites formation and tumor lymphangiogenesis.
Hsieh CY; Chen CA; Chou CH; Lai KP; Jeng YM; Kuo ML; Wei LH
J Biomed Sci; 2004; 11(2):249-59. PubMed ID: 14966375
[TBL] [Abstract][Full Text] [Related]
12. Elevated expression of protein tyrosine kinase c-Yes, but not c-Src, in human malignant melanoma.
Loganzo F; Dosik JS; Zhao Y; Vidal MJ; Nanus DM; Sudol M; Albino AP
Oncogene; 1993 Oct; 8(10):2637-44. PubMed ID: 7690926
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of HER-2/neu in uterine serous papillary cancer.
Santin AD; Bellone S; Gokden M; Palmieri M; Dunn D; Agha J; Roman JJ; Hutchins L; Pecorelli S; O'Brien T; Cannon MJ; Parham GP
Clin Cancer Res; 2002 May; 8(5):1271-9. PubMed ID: 12006548
[TBL] [Abstract][Full Text] [Related]
14. Protein tyrosine phosphatase epsilon activates Yes and Fyn in Neu-induced mammary tumor cells.
Granot-Attas S; Elson A
Exp Cell Res; 2004 Mar; 294(1):236-43. PubMed ID: 14980517
[TBL] [Abstract][Full Text] [Related]
15. Aberrant expression of proteinase-activated receptor 4 promotes colon cancer cell proliferation through a persistent signaling that involves Src and ErbB-2 kinase.
Gratio V; Walker F; Lehy T; Laburthe M; Darmoul D
Int J Cancer; 2009 Apr; 124(7):1517-25. PubMed ID: 19058300
[TBL] [Abstract][Full Text] [Related]
16. Src family kinase members have a common response to histone deacetylase inhibitors in human colon cancer cells.
Hirsch CL; Smith-Windsor EL; Bonham K
Int J Cancer; 2006 Feb; 118(3):547-54. PubMed ID: 16094635
[TBL] [Abstract][Full Text] [Related]
17. Activation of stat3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated SRC and survivin expression.
Diaz N; Minton S; Cox C; Bowman T; Gritsko T; Garcia R; Eweis I; Wloch M; Livingston S; Seijo E; Cantor A; Lee JH; Beam CA; Sullivan D; Jove R; Muro-Cacho CA
Clin Cancer Res; 2006 Jan; 12(1):20-8. PubMed ID: 16397019
[TBL] [Abstract][Full Text] [Related]
18. c-Yes tyrosine kinase activity in human colon carcinoma.
Park J; Meisler AI; Cartwright CA
Oncogene; 1993 Oct; 8(10):2627-35. PubMed ID: 7690925
[TBL] [Abstract][Full Text] [Related]
19. Increased tyrosine kinase activity of c-Src during calcium-induced keratinocyte differentiation.
Zhao Y; Sudol M; Hanafusa H; Krueger J
Proc Natl Acad Sci U S A; 1992 Sep; 89(17):8298-302. PubMed ID: 1381508
[TBL] [Abstract][Full Text] [Related]
20. Neu oncogene expression in ovarian tumors: a quantitative study.
Huettner PC; Carney WP; Naber SP; DeLellis RA; Membrino W; Wolfe HJ
Mod Pathol; 1992 May; 5(3):250-6. PubMed ID: 1353878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
